Silex Systems Limited · ASX:SLX
Silex Systems — Investor Presentation (May 2024)
21 slides from Silex Systems's investor presentation, May 15, 2024
Slide 1: Investor Presentation ASX announcement cover note
Investor Presentation 15 May 2024 Silex Systems Limited (Silex) (ASX: SLX; OTCQX: SILXY) is providing the attached presentation to support upcoming Investor Relations activities. The presentation highlights recent US Government initiatives aimed at supporting revitalisation of the nuclear fuel indus
Slide 2: Authorisation and contact details
Authorised for release by the Silex Board of Directors. Further information on the Company’s activities can be found on the Silex website: www.silex.com.au or by contacting: Michael Goldsworthy Julie Russell CEO/Managing Director CFO/Company Secretary T +61 2 9704 8888 T +61 2 9704 8888 E investor.r
Slide 3: Silex Systems Limited Investor Presentation
Silex Systems Limited For personal use only Investor Presentation (ASX: SLX) (OTCQX: SILXY) Dr Michael Goldsworthy CEO/Managing Director 15 May 2024 www.silex.com.au 1
Slide 4: Forward Looking Statements and Risk Factors
Forward Looking Statements and Risk Factors About Silex Systems Limited (ASX: SLX) (OTCQX: SILXY) Silex Systems Limited ABN 69 003 372 067 (Silex or Company) is a technology commercialisation company whose primary asset is the SILEX laser enrichment technology, originally developed at the Company’s
Slide 5: Our Mission: commercialise SILEX laser enrichment technology
Our Mission: to commercialise the unique SILEX laser enrichment technology for application to: For personal use only Uranium production and Silicon enrichment Medical isotope enrichment enrichment (silicon quantum computing) (new cancer therapies) (nuclear power) Our strategy is focused on extractin
Slide 6: Highlights and Recent Developments
Highlights and Recent Developments Global Laser Enrichment (GLE) / SILEX Uranium Enrichment Technology Project: • Through commercialisation of the SILEX technology, GLE is positioning to leverage the ‘Triple Opportunity’ that has emerged in the global nuclear fuel market as a result of energy decarb
Slide 7: Primary Focus on GLE Commercialisation
Primary Focus on GLE Commercialisation Uranium production and enrichment For personal use only (nuclear power) • SILEX uranium technology licensee Global Laser Enrichment (GLE) is progressing towards commercialisation • US-based GLE under JV ownership since 2021: 51% by Silex and 49% by Cameco Corpo
Slide 8: Nuclear Fuel Supply and Current Issues
Nuclear Fuel Supply and Current Issues The Nuclear Fuel Supply Chain For personal use only SILEX/GLE Opportunities Issues facing the Global Nuclear Fuel Supply Chain: - Western supply chain recent history – curtailments and under-investment in resources and production capability - Supply chain risks
Slide 9: US and EU Nuclear Fuel Requirements Supplied by Russia
US and EU Nuclear Fuel Requirements Supplied by Russia Russian Share of Global EU Nuclear Fuel US Nuclear Fuel Production Capacity1 Supplied by Russia2 Supplied by Russia1,3 Uranium (U308) ~14% ~20% ~14% For personal use only Conversion ~27% ~25% ~18% Enrichment (SWU) ~45% ~31% ~24% • Major concerns
Slide 10: Favourable Nuclear Fuel Market Price Trends
Favourable Nuclear Fuel Market Price Trends For personal use only Source: UxC • Global nuclear fuel markets are pricing in the impact of a bifurcating market precipitated by Russian nuclear fuel sanctions • Uranium term prices reflect significant increase in term contracting as a result of supply-de
Slide 11: Acceleration of GLE's Activities for the SILEX technology
Acceleration of GLE’s Activities for the SILEX technology GLE has unique potential to address the ‘Triple Opportunity’ that has emerged in the global nuclear fuel supply chain: • GLE joint venture owners, Silex and Cameco, approved a plan and budget for GLE in CY2024 that continues to support the ac
Slide 12: GLE's Potential Timelines for Commercialisation of SILEX technology
GLE’s Potential Timelines for Commercialisation of SILEX technology1 Baseline - GLE Commercialisation Timeline: PLEF Commercial Technology Demonstration2 PLEF3 Feasibility and Licensing PLEF EPC4 Operations For personal use only c. 2025 c. 2027 c. 2030+ Accelerated - GLE Commercialisation Timeline5:
Slide 13: Status of Technology Pilot Demonstration Project
Status of Technology Pilot Demonstration Project1 Pilot Laser Systems: - Two full-scale pilot laser system modules (designed and built by Silex) installed and commissioned in GLE’s Test Loop facility in Wilmington - Currently being integrated within the pilot enrichment facility in preparation for T
Slide 14: GLE's PLEF Production Plant Opportunity
GLE’s PLEF Production Plant Opportunity The PLEF Triple Opportunity Paducah Laser Enrichment Facility (PLEF) – an opportunity to deploy the SILEX technology in the US: • PLEF UF6 Production: Production of up to 5 million pounds (equivalent) natural grade uranium (as UF6) annually for up to 30 years
Slide 15: GLE's PLEF Multi-purpose Production Plant Opportunity
GLE’s PLEF Multi-purpose Production Plant Opportunity For personal use only Source: GLE, Multi-purpose PLEF (conceptual) www.silex.com.au 13
Slide 16: GLE's PLEF Production Plant Opportunities
GLE’s PLEF Production Plant Opportunities For personal use only * * GLE PLEF Process Streams – NUF6 and LEU Production * DUF6: Depleted UF6 www.silex.com.au 14
Slide 17: PLEF UF6 Production Opportunity
PLEF UF6 Production Opportunity (Natural UF6 production from tails) Akin to a ‘Tier 1’ Potential Accelerated Equivalent U3O8 Uranium Resource* Production For personal use only Commercial Based on low cost and Operation Date^ longevity of production Up to 5 million lbs p.a. for approximately 30 years
Slide 18: GLE Value Proposition for Silex
GLE Value Proposition for Silex* 1) GLE Equity – Minimum 25%: • Silex currently holds 51% – Cameco has a call Option to acquire an additional 26% at fair market value • Option window opened 1 February 2023 – closes 30 months after successful TRL-6 demonstration For personal use only • Either way, Si
Slide 19: Significant Additional Opportunities
Significant Additional Opportunities For personal use only Silicon enrichment Medical isotope enrichment (silicon quantum computing) (new targeted beta cancer therapies) • SILEX technology proven capable of producing highly enriched silicon • Medical isotope project aiming to develop a process to en
Slide 20: Summary
Summary GLE’s path to market is underpinned by the PLEF UF6 project for cost effective production of natural uranium (in the form of UF6) and significant value of conversion contained in GLE’s feed inventories Acceleration of the technology pilot demonstration project continuing in CY2024, which, if
Slide 21: Thank you
For personal use only Thank you www.silex.com.au 19